The cost-effectiveness of screening for type 2 diabetes.
Context. - Type 2 diabetes mellitus is a common and serious disease in the United States, but one third of those affected are unaware they have it.
- To estimate the cost-effectiveness of early detection and treatment of type 2 diabetes.
- A Monte Carlo computer simulation model was developed to estimate the lifetime costs and benefits of 1-time opportunistic screening (ie, performed during routine contact with the medical care system) for type 2 diabetes and to compare them with current clinical practice.
Cost-effectiveness was estimated for all persons aged 25 years or older, for age-specific subgroups, and for African Americans.
Data were obtained from clinical trials, epidemiologic studies, and population surveys, and a single-payer perspective was assumed.
Costs and benefits are discounted at 3% and costs are expressed in 1995 US dollars.
- Single-payer health care system.
- Hypothetical cohort of 10000 persons with newly diagnosed diabetes from the general US population.
Main Outcome Measures
- Cost per additional life-year gained and cost per quality-adjusted life-year (QALY) gained.
- The incremental cost of opportunistic screening among all persons aged 25 years or older is estimated at $236 449 per life-year gained and $56 649 per QALY gained.
Screening is more cost-effective among younger people and among African Americans. (...)
Mots-clés Pascal : Diabète non insulinodépendant, Dépistage, Précoce, Arbre décision, Exploration clinique, Diagnostic, Analyse coût efficacité, Homme, Etats Unis, Amérique du Nord, Amérique, Endocrinopathie, Economie santé
Mots-clés Pascal anglais : Non insulin dependent diabetes, Medical screening, Early, Decision tree, Clinical investigation, Diagnosis, Cost efficiency analysis, Human, United States, North America, America, Endocrinopathy, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0019865
Code Inist : 002B21E01A. Création : 31/05/1999.